[ Englisch] How Are MPN Patients Monitored?

Published on

Topics include: Understanding

What tests are important for an MPN patient as they go on their journey? MPN Expert, Dr. Srdan Verstovsek, explains.

The Ask the Expert series is sponsored through an education grant to the Patient Empowerment Network from Incyte Corporation.

View more programs featuring

Transcript

Then you follow patients prospectively, meaning see patients at certain time periods.  You look at their spleen.  You look at their symptoms.  You look at their blood cell count, chemistry.  Those are easy to get—no special testing needed other than blood taking and physical exam, talking to the patients.  If the patient is stable, really there is no mandatory checking of the bone marrow because, I mean, the disease, unfortunately, is not going get better or go away. 

We worry more about a change in this long?term follow?up of the blood count and physical exam.  If there is significant change, then we do a bone marrow and see whether the bone marrow change is what is causing a drop in the red blood cell count and worsening anemia, or is the bone marrow becoming more fibrotic, so we need to do something about it, or there is a change in baby cells called blasts, or the patient, god forbid, is changing to acute leukemia over time.  So bone marrows are done in everyday practice usually when there is a need to explain the change in the simple test of blood and physical exam symptoms. 

The role of the ultrasound or CAT scan or MRI or others is on the side, I would say.  It's not mandatory for one to have an ultrasound to see about the spleen size every year or so or even at the beginning.  Those enlargements that are palpable, that you can feel, are usually clinically irrelevant, and you can easily measure with a tape, for example, the spleen or the liver.  Now, they are useful to have over time, but they are not mandatory.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you

Related Programs

Where Do We Stand with JAK Inhibitors in Development?

Are there additional JAK inhibitors in development? Dr. Claire Harrison, a leading MPN researcher, discusses JAK inhibitor drugs currently in clinical trials.

Published:

Advances in Understanding and Treating MPNs

Dr. Srdan Verstovsek, a world-renowned researcher from MD Anderson Cancer Center, explores what he describes as "unprecedented developments" in the understanding of myeloproliferative neoplasms (MPNs) and how new research could lead to more effective treatment.

Published:

Exciting Data on Developing Drugs for Myelofibrosis

Over the past year, there has been continued progress in improving treatments for myelofibrosis. Watch now as Dr. Claire Harrison shares updated news from the Comfort II study, including how patients are responding to the treatment regimen with few side effects.

Published:

Advertisement
tritt unserer Gemeinschaft bei Registrieren Sie sich für Veranstaltungen Lesen Sie unseren neuesten Blog
Advertisement

Page last updated on May 2, 2014